EVG Stock Overview
Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.057|
|52 Week High||UK£0.13|
|52 Week Low||UK£0.042|
|1 Month Change||-6.56%|
|3 Month Change||-20.28%|
|1 Year Change||-33.72%|
|3 Year Change||-67.43%|
|5 Year Change||-75.22%|
|Change since IPO||-83.77%|
Recent News & Updates
We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|EVG||GB Biotechs||GB Market|
Return vs Industry: EVG underperformed the UK Biotechs industry which returned 23.9% over the past year.
Return vs Market: EVG underperformed the UK Market which returned 10.5% over the past year.
|EVG Average Weekly Movement||6.1%|
|Biotechs Industry Average Movement||6.0%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: EVG is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: EVG's weekly volatility (6%) has been stable over the past year.
About the Company
Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company’s lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections.
Evgen Pharma Fundamentals Summary
|EVG fundamental statistics|
Is EVG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EVG income statement (TTM)|
|Cost of Revenue||UK£3.39m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
Dec 07, 2021
|Earnings per share (EPS)||-0.0097|
|Net Profit Margin||-1,378.35%|
How did EVG perform over the long term?See historical performance and comparison
Is Evgen Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EVG is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.
PE vs Market: EVG is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVG is good value based on its PB Ratio (1.3x) compared to the GB Biotechs industry average (6.1x).
How is Evgen Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EVG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EVG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EVG is forecast to have no revenue next year.
High Growth Revenue: EVG is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EVG is forecast to be unprofitable in 3 years.
How has Evgen Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVG is currently unprofitable.
Growing Profit Margin: EVG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EVG is unprofitable, but has reduced losses over the past 5 years at a rate of 4.8% per year.
Accelerating Growth: Unable to compare EVG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).
Return on Equity
High ROE: EVG has a negative Return on Equity (-22.64%), as it is currently unprofitable.
How is Evgen Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: EVG's short term assets (£12.3M) exceed its short term liabilities (£607.0K).
Long Term Liabilities: EVG has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVG is debt free.
Reducing Debt: EVG had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EVG has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 9% each year.
What is Evgen Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Huw Jones (61 yo)
Dr. Huw Jones, BSc, Ph.D. serves as Chief Executive Officer at Evgen Pharma plc since October 1, 2020. He has been Chief Executive Officer at Chronos Therapeutics Ltd. since December 2012 and serves as its...
CEO Compensation Analysis
Compensation vs Market: Huw's total compensation ($USD296.71K) is about average for companies of similar size in the UK market ($USD322.34K).
Compensation vs Earnings: Insufficient data to compare Huw's compensation with company performance.
Experienced Management: EVG's management team is considered experienced (2.5 years average tenure).
Experienced Board: EVG's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100.2%.
Evgen Pharma plc's employee growth, exchange listings and data sources
- Name: Evgen Pharma plc
- Ticker: EVG
- Exchange: AIM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£15.669m
- Shares outstanding: 274.89m
- Website: https://evgen.com
Number of Employees
- Evgen Pharma plc
- Alderley Park, Block 24
- Suite 24G13
- Nether Alderley
- SK10 4TG
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/03 21:21|
|End of Day Share Price||2021/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.